A June–September roundup spanning hepatitis research and surveillance data, FDA and ACIP policy moves, diet and diagnostics insights, and pipeline updates from screening innovations to HBV/HDV/HCV trials and approvals.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *